MARKET

AERI

AERI

Aerie Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.33
+0.36
+2.78%
After Hours: 13.33 0 0.00% 16:00 07/10 EDT
OPEN
13.20
PREV CLOSE
12.97
HIGH
13.52
LOW
12.93
VOLUME
654.62K
TURNOVER
--
52 WEEK HIGH
26.34
52 WEEK LOW
10.80
MARKET CAP
619.42M
P/E (TTM)
-3.0250
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average AERI stock price target is 32.33 with a high estimate of 50.00 and a low estimate of 16.00.

EPS

AERI News

More
Is Aerie Pharmaceuticals a Buy?
Wall Street has given the eye-care specialist the cold shoulder in 2020. Is that an opportunity for individual investors?
Motley Fool · 07/02 12:11
Aerie Pharmaceuticals Inc (AERI): Hedge Funds Are Nibbling
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter
Insider Monkey · 06/15 22:04
Aerie Pharmaceuticals Appoints Peter J. McDonnell, M.D., to the Companys Board of Directors
Business Wire · 06/11 11:30
Aerie Looks Modestly Undervalued Despite High Cash Burn
Seeking Alpha - Article · 06/06 13:33
Aerie (AERI) Up 1.9% Since Last Earnings Report: Can It Continue?
Aerie (AERI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 06/05 15:31
Edited Transcript of AERI earnings conference call or presentation 6-May-20 9:00pm GMT
Thomson Reuters StreetEvents · 06/03 08:40
Oppenheimer Maintains Outperform on Aerie Pharmaceuticals, Raises Price Target to $24
Oppenheimer maintains Aerie Pharmaceuticals (NASDAQ:AERI) with a Outperform and raises the price target from $22 to $24.
Benzinga · 06/01 15:38
Was The Smart Money Right About Aerie Pharmaceuticals Inc (AERI)?
Hedge funds don't get the respect they used to get. Nowadays investors prefer passive funds over actively managed funds. One thing they don't realize is that 100% of the passive funds didn't see the coronavirus recession coming, but a lot of hedge funds did. E
Insider Monkey · 05/11 23:15

Industry

Biotechnology & Medical Research
-0.39%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About AERI

Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company's product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan). The Company's product candidates are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. Its Rhopressa is a once-daily eye drop. Rhopressa inhibits Rho kinase (ROCK), and the norepinephrine transporter (NET), which are both biochemical targets for lowering IOP. Its Roclatan is a once-daily, fixed-dose combination of Rhopressa and latanoprost, which is a prescribed drug for the treatment of patients with open-angle glaucoma. The Company is engaged in conducting Phase III clinical trial for Roclatan.
More

Webull offers kinds of Aerie Pharmaceuticals Inc stock information, including NASDAQ:AERI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AERI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AERI stock methods without spending real money on the virtual paper trading platform.